• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    10/28/24 4:06:51 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email
    SC 13G/A 1 d856443dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    TELA Bio, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    872381108

    (CUSIP Number)

    Martin P. Sutter

    EW Healthcare Partners Fund 2, L.P.

    21 Waterway Avenue, Suite 225

    The Woodlands, Texas 77380

    (281) 364-1555

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 24, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Fund 2, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     1,615,368

       6  

     SHARED VOTING POWER

     

     -0-

       7  

     SOLE DISPOSITIVE POWER

     

     1,615,368

       8  

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,615,368

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     4.10%

    12  

     TYPE OF REPORTING PERSON

     

     PN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Fund 2-A, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     2,495,341

       6  

     SHARED VOTING POWER

     

     -0-

       7  

     SOLE DISPOSITIVE POWER

     

     2,495,341

       8  

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,495,341

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     6.34%

    12  

     TYPE OF REPORTING PERSON

     

     PN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Fund 2-UGP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,110,709

       6  

     SHARED VOTING POWER

     

     -0-

       7  

     SOLE DISPOSITIVE POWER

     

     4,110,709

       8  

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,110,709

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     10.44%

    12  

     TYPE OF REPORTING PERSON

     

     CO


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Fund 2-GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,110,709

       6  

     SHARED VOTING POWER

     

     -0-

       7  

     SOLE DISPOSITIVE POWER

     

     4,110,709

       8  

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,110,709

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     10.44%

    12  

     TYPE OF REPORTING PERSON

     

     PN


    SCHEDULE 13G/A

    Explanatory Note

    This Amendment No. 1 to Schedule 13G (“Amendment No. 1”) is filed by EW Healthcare Partners Fund 2, L.P., a Delaware limited partnership (“EWHP2”), EW Healthcare Partners Fund 2-A, L.P., a Delaware limited partnership (“EWHP2-A”), EW Healthcare Partners Fund 2-GP, L.P., a Delaware limited partnership (“EWHP2 GP”), and EW Healthcare Partners Fund 2-UGP, LLC, a Delaware limited liability company (“EWHP2 General Partner” and collectively with EWHP2, EWHP2-A and EWHP2 GP, the “EWHP Investors” or the “Reporting Persons”), and relates to shares of common stock, par value $0.001 per share (“Common Stock”), of TELA Bio, Inc. (the “Issuer”). This Amendment No. 1 is being filed solely to report a decrease of the EWHP Investors’ beneficial ownership of the Issuer’s Common Stock by more than 5% as a result of the Issuer’s underwritten public offering, which closed on October 24, 2024.

    Item 1.

    (a) Name of Issuer: TELA Bio, Inc.

    (b) Address of Issuer’s Principal Executive Offices: 1 Great Valley Parkway, Suite 24, Malvern, PA 19355.

    Item 2.

    (a) Name of Person Filing: This Amendment No. 1 is being filed jointly by the Reporting Persons.

    (b) Address of Principal Business Office: The address of the principal business of each of the Reporting Persons is 21 Waterway, Suite 225, The Woodlands, Texas 77380.

    (c) Citizenship: (i) EWHP2, EWHP2-A, and EWHP2 GP are each Delaware limited partnerships; and (ii) EWHP2 General Partner is a Delaware limited liability company.

    (d) Title and Class of Securities: Common Stock, par value $0.001 per share.

    (e) CUSIP Number: 872381108.

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a 8).
    (e)    ☐    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a 3);
    (j)    ☐    Group, in accordance with 240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.(1)


    (a) Amount Beneficially Owned.

    For EWHP2, 1,615,368 shares.

    For EWHP2-A, 2,495,341 shares.

    For EWHP2 GP, 4,110,709 shares.

    For EWHP2 General Partner, 4,110,709 shares.

    (b) Percent of Class.(2)

    For EWHP2, 4.10%.

    For EWHP2-A, 6.34%.

    For EWHP2 GP, 10.44%.

    For EWHP2 General Partner, 10.44%.

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    For EWHP2, 1,615,368 shares.

    For EWHP2-A, 2,495,341 shares.

    For EWHP2 GP, 4,110,709 shares.

    For EWHP2 General Partner, 4,110,709 shares.

    (ii) Shared power to vote or to direct the vote:

    For EWHP2, 0 shares.

    For EWHP2-A, 0 shares.

    For EWHP2 GP, 0 shares.

    For EWHP2 General Partner, 0 shares.

    (iii) Sole power to dispose or to direct the disposition of:

    For EWHP2, 1,615,368 shares.

    For EWHP2-A, 2,495,341 shares.

    For EWHP2 GP, 4,110,709 shares.

    For EWHP2 General Partner, 4,110,709 shares.

    (iv) Shared power to dispose or to direct the disposition of:

    For EWHP2, 0 shares.

    For EWHP2-A, 0 shares.

    For EWHP2 GP, 0 shares.

    For EWHP2 General Partner, 0 shares.

     

    (1)

    The managers of EWHP2 General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman and Petri Vainio (collectively, the “Managers”). The Managers may exercise voting and investment control over the shares of Common Stock only by majority action of the Managers. Each individual Manager disclaims beneficial ownership over the shares of Common Stock except to the extent of his respective pecuniary interest therein.

    (2)

    Based on an aggregate 39,383,798 shares of Common Stock outstanding as of October 24, 2024, which is based on (i) 24,713,798 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report for the quarter ended June 30, 2024, filed with the U.S. Securities and Exchange Commission on August 13, 2024, and (ii) 14,670,000 shares of Common Stock issued in connection with the Issuer’s underwritten public offering, which closed on October 24, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.


    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Date: October 28, 2024

     

    EW HEALTHCARE PARTNERS FUND 2, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2-A, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2-UGP, LLC
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2 GP, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director


    JOINT FILING AGREEMENT

    Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Common Stock of TELA Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G/A as to any of the undersigned upon such person giving written notice thereof to each of the other persons signature hereto, at the principal office thereof.

    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Date: October 28, 2024

     

    EW HEALTHCARE PARTNERS FUND 2, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2-A, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2-UGP, LLC
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    EW HEALTHCARE PARTNERS FUND 2 GP, L.P.
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    Get the next $TELA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her ac

      5/9/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:26:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:59 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony bought $199,998 worth of shares (88,888 units at $2.25), increasing direct ownership by 24% to 458,897 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:31 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Talmo Paul covered exercise/tax liability with 190 shares, decreasing direct ownership by 0.15% to 123,882 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:49:36 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Accounting Officer Smeykal Megan covered exercise/tax liability with 96 shares, decreasing direct ownership by 0.26% to 36,831 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:46:56 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony covered exercise/tax liability with 384 shares, decreasing direct ownership by 0.07% to 590,110 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:45:22 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TELA Bio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

      3/21/25 8:05:03 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on TELA Bio with a new price target

      Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

      5/31/22 9:13:36 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    SEC Filings

    See more
    • SEC Form 10-Q filed by TELA Bio Inc.

      10-Q - TELA Bio, Inc. (0001561921) (Filer)

      5/8/25 4:30:27 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      5/8/25 4:15:49 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

      SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      5/8/25 7:57:51 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    See more
    • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

      MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

      6/4/24 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

      MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

      5/20/24 4:03:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

      MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where

      4/8/24 7:00:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Financials

    Live finance-specific insights

    See more
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

      3/20/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      11/14/24 1:06:57 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by TELA Bio Inc.

      SC 13G - TELA Bio, Inc. (0001561921) (Subject)

      10/29/24 5:12:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      10/28/24 4:06:51 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care